Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

DOR BioPharma Receives FDA Orphan Drug Designation For OrBec(R) For The Treatment Of Chronic Gastrointestinal GVHD
DOR BioPharma, Inc., (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Oral BDP (beclomethasone 17,21-dipropionate, or orBec((R))) for the treatment of gastrointestinal symptoms associated with chronic Graft-versus-Host disease (cGVHD) in patients who have undergone allogeneic hematopoietic cell transplantation.

World Heart Federation Warns That Burden Of Tobacco Epidemic Continues To Worsen Societies And Economies
G-20 leaders pledged to provide the International Monetary Fund with $500
News of the day
Induction Of Labour After 37 Weeks Recommended For Women With Gestational Hypertension/Mild Pre-Eclampsia (Hypitat Study)
Pregnant women with mild hypertensive disorders such as high blood pressure/mild pre-eclampsia^ should have their labour induced once they complete 37 weeks of their pregnancy. This is the conclusion of the HYPITAT study, published in an Article Online First and in an upcoming edition of The Lancet, written by Dr Corine M Koopmans, Department of Obstetrics and Gynaecology, University Medical Centre Groningen, Netherlands, and colleagues.
Medical Devices

Ablynx Announces A Novel Preclinical Development Candidate Targeting IL6R

Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced that it has advanced ALX-0061, a new Nanobody®-based therapeutic programme, into preclinical development for the treatment of autoimmune and inflammatory diseases. ALX-0061 is a selective, low molecular weight biologic, binding to the IL6 receptor (IL6R). It has a very high potency and demonstrated a favourable PD, PK and safety profile in preclinical testing compared with the benchmark molecule. ALX-0061 has no Fc-mediated effector function which may translate into an improved safety profile. It also avoids cross-linking IL6R due to its monovalent binding to the target. The low molecular weight and desirable biophysical properties of this Nanobody® open up opportunities for alternative routes of administration and superior tissue penetration in the clinical setting. The Nanobody® can be manufactured at a relatively low cost in a microbial system. "We are delighted to strengthen our product portfolio by advancing another novel Nanobody®, discovered using our proprietary Nanobody® platform, into preclinical development. It is well positioned to translate into a superior treatment for rheumatoid arthritis and other autoimmune diseases. There are already three Nanobodies® in clinical development, with our lead programme, ALX-0081, a novel anti-thrombotic, on track to start Phase II in the next few months", commented Dr. Edwin Moses, Chief Executive Officer and Chairman of Ablynx. About ALX-0061 (IL6R) ALX-0061 is a Nanobody® binding to the interleukin-6 receptor (IL6R). It has the potential to differentiate through its high potency, high stability and low molecule weight of only 26kD which should translate into superior tissue penetration, attractive PK/PD and superior safety and efficacy profile compared with a benchmark monoclonal antibody. The involvement of the IL6 pathway in a variety of diseases indicates that multiple indications can be pursued with large market potential including rheumatoid arthritis (RA), Crohn"s disease, Castleman"s disease, multiple myeloma and systemic lupus erythematosus (SLE). College Hill Life Sciences


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009